Insulin Safety Week 2024 – Hybrid closed loop in pregnancy webinar

Healthcare professionals are encouraged to book their place on a free educational webinar in the run up to Insulin Safety Week 2024.

Aligned with the theme of Insulin Safety Week 2024, which emphasises the safe utilisation of diabetes technology, Dr Helen Murphy and Dr Tara Lee will deliver an online educational session on Thursday, May 16.

The webinar will feature a comprehensive overview of recent advancements in diabetes technology that are revolutionising the management of diabetes during pregnancy and beyond. Attendees will gain insights into which hybrid closed loop systems offer the most significant clinical advantages for both mothers and babies.

Dr Helen Murphy, Professor of Medicine at the University of East Anglia and practicing clinician, said: “Created to increase confidence amongst healthcare professionals in initiating and optimising hybrid closed loop systems, this practical session will help healthcare professionals understand the impact and benefits of available systems.”

Free to attend, healthcare professionals can book their place on the webinar here. 

The nationwide campaign Insulin Safety Week 2024, held July 1-7, is open to all healthcare professionals working in diabetes care.

Providing comprehensive printed and online resources to increase understanding of the new technology, healthcare professionals can register for their resource pack by emailing registrations@ojpr.co.uk with the following information:

  • Lead organiser’s name

  • Name of trust/organisation

  • Number of participating sites (including names of each)

  • Telephone number

  • Address for printed pack

  • If you require t-shirts and amount (up to 4)

Insulin Safety Week 2024 is organised by Orange Juice Communications and has been funded by Embecta, GlucoRx, Medtronic, Sanofi and Ypsomed which have had no input into any arrangements or content.

For more information about Insulin Safety Week 2024 visit www.insulinsafetyweek.com.

Previous
Previous

New SGLT2 inhibitors prescribing decision tool now available

Next
Next

Recruitment underway for pioneering type 1 diabetes clinical trial